会员登录 - 用户注册 - 设为首页 - 加入收藏 - 网站地图 【emo's not dead cruise 2024 lineup】5 Stocks Analysts Recommend Heading Into 2020!

【emo's not dead cruise 2024 lineup】5 Stocks Analysts Recommend Heading Into 2020

时间:2024-09-29 12:27:12 来源:k 3 i y 3 0 o n 4 k s e 6 p l 8 o i t c j q 作者:Encyclopedia 阅读:145次

Theemo's not dead cruise 2024 lineup S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020. Here’s a look at several stocks analysts recommend.

Vivint Solar Inc (NYSE:

【emo's not dead cruise 2024 lineup】5 Stocks Analysts Recommend Heading Into 2020


VSLR

【emo's not dead cruise 2024 lineup】5 Stocks Analysts Recommend Heading Into 2020


)

【emo's not dead cruise 2024 lineup】5 Stocks Analysts Recommend Heading Into 2020


Vivint shares doubled in 2019, but analysts see more upside ahead in the long-term for Vivint. Of the last 10 analysts to publish research on Vivint, nine gave the stock a bullish rating with an average price target of $9.03, suggesting 18% upside.


Glu Mobile Inc. (NASDAQ:


GLUU


)


Investors have few chances to buy stocks at a discount after the market’s big run in 2019, but Gluu shares are down 24% on the year. Gluu reported disappointing numbers and issued lackluster guidance this year, but Wall Street sees the sell-off as a buying opportunity.


The 10 most recent research reports on the company resulted in nine bullish ratings with an $8.28 average price target, suggesting 35% upside.


Viking Therapeutics Inc (NASDAQ:


VKTX


)


Viking is a clinical-stage biotech stock developing VK2809, a drug used to treat non-alcoholic steatohepatitis (NASH). Analysts are optimistic about VK2809 given there are currently no other treatments for NASH, which could potentially represent a $35 billion per year market.


In fact, Wall Street is so bullish on Viking that all 10 of the most recent analyst ratings for the stock have been bullish with an average price target of $22.75, suggesting 160% upside.


Catalyst Pharmaceuticals Inc (NASDAQ:


CPRX


)


Like Vivint, biotech stock Catalyst Pharmaceuticals more than doubled in 2019, but analysts say the stock may be just getting started. Management recently said its Firdapse treatment for muscle disorder Lambert-Eaton myasthenic syndrome (LEMS) could generate up to $155 million in 2020 revenue, but competition from Jacobus Pharma’s Ruzurgi could create pricing risk in the near-term.


Nine of 10 most recent analysts to publish research on the stock are bullish with an average price target of $6.94, suggesting 73% upside.


Amazon.com, Inc. (NASDAQ:


AMZN


)


Another year has come and gone, and the Amazon train just keeps on rolling down the tracks. Amazon shares gained another 19.9% in 2019, and Wall Street analysts say e-commerce sales and cloud services growth will produce even more upside in 2020.


Amazon has a ton of analyst coverage, and nine out of the last 10 analysts have been bullish on the stock with an average price target of $2,190, suggesting 22% upside.


Benzinga's Take


Wall Street analysts are far from perfect in their stock recommendations and forecasts. However, investors can be slightly more confident when there is a clear consensus among analysts that cover a particular stock.


Story continues


Do you agree with this take? Email


[email protected]


with your thoughts.


Related Links:


10 Worst Performing S&P 500 Stocks Of 2019


10 Best Performing S&P 500 Stocks Of 2019


Latest Ratings for AMZN


Dec 2019


Assumes


Buy


Nov 2019


Initiates Coverage On


Hold


Oct 2019


Maintains


Market Outperform


View More Analyst Ratings for AMZN


View the Latest Analyst Ratings


0


See more from Benzinga


10 Best Performing S&P 500 Stocks Of The Decade


Here's How Much Investing 0 In Amazon Stock Back In 2010 Would Be Worth Today


Gene Munster Talks Tesla's Opportunity, Apple's Valuation, Netflix's Headwinds


© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


View comments


(责任编辑:Entertainment)

相关内容
  • FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against HDFC Bank Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  • MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages CKH, PS, WDR, and EIDX Shareholders to Contact the Firm
  • CanWel Building Materials Group (TSE:CWX) Shareholders Have Felt Some Pain With A 19% Loss On Their Investment
  • What's in Store for Ambarella (AMBA) This Earnings Season?
  • Snapchat Ousts Trump’s Account From Discover Section
  • Coronavirus spread in Canada is slowing - Public Health Agency
  • What Is Parker-Hannifin's (NYSE:PH) P/E Ratio After Its Share Price Tanked?
  • Is the Options Market Predicting a Spike in Seagate (STX) Stock?
推荐内容
  • Guggenheim Energy & Income Fund Announces Tender Offer
  • Baker Hughes Snaps Up Compact Carbon Capture For Energy Transition Path
  • LATAM Airlines Group: Q1 Earnings Insights
  • ValOre Initiates Multi-faceted Optimization Testwork at Pedra Branca and Receives Preliminary Platsol™ Metallurgical Recoveries of 93.4% for Palladium and 95.3% for Platinum
  • Sientra to Present at the William Blair 40th Annual Growth Stock Conference
  • CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition